Score Pharma is redefining the development of next-generation antibody therapeutics through a proprietary process chemistry that enables rapid, low-risk development of second-generation biosuperiors by leveraging existing clinically validated product-producing cell lines. Use of the platform shortens development timelines, reduces cost and risk, while maintaining manufacturability, enhancing Fc function and efficacy across proven therapeutic classes without re-engineering full production systems. The lead program, a biosuperior anti-HER2 trastuzumab, is being advanced for breast cancer in partnership with Southern Research, and our cell line development partner, Asimov, demonstrates the platform’s scalability and commercial potential. By unlocking a faster, capital-efficient path to enhanced biologics, Score Pharma is positioned to lead the emerging biosuperior antibody market and build a high-value pipeline of differentiated antibody therapeutics.